Wirkungen von Liraglutid auf kardiovaskuläre Ereignisse bei Patienten der LEADER-Studie mit oder ohne Herzinsuffizienz in der Vorgeschichte

Autor: H Askelund Sævereid, M Husain, SC Bain, JFE Mann, MA Nauck, NR Poulter, B Goldman, A Bloch Thomsen, SP Marso

Publikováno v: Diabetes – Nicht nur eine Typ-Frage – www.diabeteskongress.de.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5b02536aaf59687b987619d91216c038
https://doi.org/10.1055/s-0039-1688301

Paclitaxel-Coated Balloon vs Uncoated Balloon for Coronary In-Stent Restenosis: The AGENT IDE Randomized Clinical Trial.

Autor: Yeh RW; Beth Israel Deaconess Medical Center, Boston, Massachusetts., Shlofmitz R; St Francis Hospital, Roslyn, New York., Moses J; Columbia University Irving Medical Center/NewYork-Presbyterian Hospital and the Cardiovascular Research Foundation, New York., Bachinsky W; University of Pittsburgh Medical Center, Harrisburg, Pennsylvania., Dohad S; Cedars Sinai Medical Center, Los Angeles, California., Rudick S; Lindner Center for Research and Education at Christ Hospital, Cincinnati, Ohio., Stoler R; Baylor Scott & White Heart and Vascular Hospital, Dallas, Texas., Jefferson BK; HCA Tristar Centennial Medical Center, Nashville, Tennessee., Nicholson W; Emory University Hospital, Atlanta, Georgia., Altman J; St Anthony Hospital, Denver, Colorado., Bateman C; South Denver Cardiology, Littleton, Colorado., Krishnaswamy A; Cleveland Clinic Foundation, Cleveland, Ohio., Grantham JA; St Luke's Hospital of Kansas City, Kansas City, Missouri., Zidar FJ; Austin Heart, Austin, Texas., Marso SP; Overland Park Regional Medical Center, Overland Park, Kansas., Tremmel JA; Stanford University Medical Center, Stanford, California., Grines C; Northside Hospital Cardiovascular Institute, Atlanta, Georgia., Ahmed MI; University of Alabama at Birmingham., Latib A; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York., Tehrani B; The Inova Schar Heart and Vascular Institute, Falls Church, Virginia., Abbott JD; Lifespan Cardiovascular Institute, Rhode Island Hospital, Providence., Batchelor W; The Inova Schar Heart and Vascular Institute, Falls Church, Virginia., Underwood P; Boston Scientific Corp, Marlborough, Massachusetts., Allocco DJ; Boston Scientific Corp, Marlborough, Massachusetts., Kirtane AJ; Columbia University Irving Medical Center/NewYork-Presbyterian Hospital and the Cardiovascular Research Foundation, New York.

Publikováno v: JAMA [JAMA] 2024 Mar 26; Vol. 331 (12), pp. 1015-1024.

Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics.

Autor: Lingvay I; Department of Internal Medicine/Endocrinology and Department of Population and Data Sciences, UT Southwestern Medical Center, Dallas, Texas, USA., Brown-Frandsen K; Novo Nordisk A/S, Søborg, Denmark., Colhoun HM; Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK., Deanfield J; Farr Institute of Health Informatics Research at London, London, UK and National Institute for Cardiovascular Outcomes Research, University College London, London, UK., Emerson SS; Department of Biostatistics, University of Washington, Seattle, Washington, USA., Esbjerg S; Novo Nordisk A/S, Søborg, Denmark., Hardt-Lindberg S; Novo Nordisk A/S, Søborg, Denmark., Hovingh GK; Novo Nordisk A/S, Søborg, Denmark., Kahn SE; Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, VA Puget Sound Health Care System and University of Washington, Seattle, Washington, USA., Kushner RF; Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Lincoff AM; Cleveland Clinic Coordinating Center for Clinical Research (C5Research) and Department of Cardiovascular Medicine, Cleveland, Ohio, USA., Marso SP; HCA Midwest Health Heart and Vascular Institute, Kansas City, Missouri, USA., Fries TM; Novo Nordisk A/S, Søborg, Denmark., Plutzky J; Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Ryan DH; Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, Louisiana, USA.

Publikováno v: Obesity (Silver Spring, Md.) [Obesity (Silver Spring)] 2023 Jan; Vol. 31 (1), pp. 111-122. Date of Electronic Publication: 2022 Dec 10.

Outcomes of retrograde chronic total occlusion percutaneous coronary intervention: A report from the OPEN-CTO registry.

Autor: Kalra S; Department of Medicine, Einstein Medical Center Philadelphia, Philadelphia, Pennsylvania., Doshi D; Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts., Sapontis J; MonashHeart, Monash University, Melbourne, Australia., Kosmidou I; Center for Interventional Vascular Therapy, Columbia University Irving Medical Center, New York, New York.; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York., Kirtane AJ; Center for Interventional Vascular Therapy, Columbia University Irving Medical Center, New York, New York.; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York., Moses JW; Center for Interventional Vascular Therapy, Columbia University Irving Medical Center, New York, New York.; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York.; St. Francis Heart Center, St. Francis Hospital, Roslyn, New York., Riley RF; Heart and Vascular Institute, The Christ Hospital, Cincinnati, Ohio., Jones P; St. Luke's Mid America Heart Institute, Kansas City, Missouri., Nicholson WJ; Department of Medicine, Wellspan York Hospital, York, Pennsylvania., Salisbury AC; St. Luke's Mid America Heart Institute, Kansas City, Missouri.; Department of Medicine, University of Missouri, Kansas City, Missouri., Lombardi WL; Department of Medicine, University of Washington Medical Center, Seattle, Washington., McCabe JM; Department of Medicine, University of Washington Medical Center, Seattle, Washington., Pershad A; Department of Medicine, Banner University Medical Center, Phoenix, Arizona., Hirai T; Department of Medicine, University of Missouri, Kansas City, Missouri., Hakemi E; Center for Interventional Vascular Therapy, Columbia University Irving Medical Center, New York, New York., Russo JJ; Ottawa Heart Institute, Ottawa, Ontario, Canada., Prasad M; Center for Interventional Vascular Therapy, Columbia University Irving Medical Center, New York, New York., Ahmad Y; Center for Interventional Vascular Therapy, Columbia University Irving Medical Center, New York, New York., Hatem R; Department of Medicine, University of Montreal, Montreal, Quebec, Canada., Gkargkoulas F; Center for Interventional Vascular Therapy, Columbia University Irving Medical Center, New York, New York., Spertus JA; Department of Medicine, University of Missouri, Kansas City, Missouri., Wyman RM; Torrance Memorial Medical Center, Torrance, California., Jaffer F; Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts., Spaedy A; Boone County Hospital, Columbia, Missouri., Cook S; Peacehealth Sacred Heart Medical Center, Springfield, Oregon., Marso SP; Research Medical Center, Kansas City, Missouri., Nugent K; St. Luke's Mid America Heart Institute, Kansas City, Missouri., Federici R; Presbyterian Health System, Albuquerque, New Mexico., Yeh RW; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts., Leon MB; Center for Interventional Vascular Therapy, Columbia University Irving Medical Center, New York, New York.; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York., Stone GW; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York.; The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Ali ZA; Center for Interventional Vascular Therapy, Columbia University Irving Medical Center, New York, New York.; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York., Parikh MA; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York.; NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York., Maehara A; Center for Interventional Vascular Therapy, Columbia University Irving Medical Center, New York, New York.; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York., Cohen DJ; Department of Medicine, University of Missouri, Kansas City, Missouri., Batres C; Center for Interventional Vascular Therapy, Columbia University Irving Medical Center, New York, New York., Grantham JA; St. Luke's Mid America Heart Institute, Kansas City, Missouri.; Department of Medicine, University of Missouri, Kansas City, Missouri., Karmpaliotis D; Center for Interventional Vascular Therapy, Columbia University Irving Medical Center, New York, New York.; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York.

Publikováno v: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions [Catheter Cardiovasc Interv] 2021 May 01; Vol. 97 (6), pp. 1162-1173. Date of Electronic Publication: 2020 Sep 02.

Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE.

Autor: Heller S; Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK., Lingvay I; Department of Internal Medicine and Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, Texas, USA., Marso SP; HCA Midwest Health Heart and Vascular Institute, Overland Park, Kansas, USA., Philis-Tsimikas A; Scripps Whittier Diabetes Institute, San Diego, California, USA., Pieber TR; Department of Internal Medicine, Medical University of Graz, Graz, Austria., Poulter NR; Imperial Clinical Trials Unit, National Heart and Lung Institute, Imperial College London, London, UK., Pratley RE; AdventHealth Translational Research Institute, Orlando, Florida, USA., Hachmann-Nielsen E; Novo Nordisk A/S, Søborg, Denmark., Kvist K; Novo Nordisk A/S, Søborg, Denmark., Lange M; Novo Nordisk A/S, Søborg, Denmark., Moses AC; Novo Nordisk A/S, Søborg, Denmark.; Independent consultant, Novo Nordisk A/S, Portsmouth, New Hampshire, USA., Andresen MT; Novo Nordisk A/S, Søborg, Denmark., Buse JB; University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.

Publikováno v: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2020 Dec; Vol. 22 (12), pp. 2241-2247. Date of Electronic Publication: 2020 Jul 09.